The importance of weight management in type 2 diabetes mellitus

Por Wilding, J P H
Publicado no Int J Clin Pract (2014)

Beyond lifestyle interventions: exploring the potential of anti‐obesity medications in the UK

Por Wilding, J. P. H.
Publicado no Clin Obes (2018)

Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure

Por Wisniacki, N, Taylor, W, Lye, M, Wilding, J P H
Publicado em 2005

Night eating syndrome: implications for severe obesity

Por Cleator, J, Abbott, J, Judd, P, Sutton, C, Wilding, J P H
Publicado em 2012

Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic‐pituitary disease

Por Deepak, D, Furlong, N J, Wilding, J P H, MacFarlane, I A
Publicado em 2007

Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution

Por Pickavance, L C, Tadayyon, M, Widdowson, P S, Buckingham, R E, Wilding, J P H
Publicado em 1999

Exposure–response analyses of liraglutide 3.0 mg for weight management

Por Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., le Roux, C. W.
Publicado no Diabetes Obes Metab (2016)

Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors

Por Daousi, C, Casson, I F, Gill, G V, MacFarlane, I A, Wilding, J P H, Pinkney, J H
Publicado em 2006

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

Por Wilding, J P H, Charpentier, G, Hollander, P, González-Gálvez, G, Mathieu, C, Vercruysse, F, Usiskin, K, Law, G, Black, S, Canovatchel, W, Meininger, G
Publicado no Int J Clin Pract (2013)